ulian Adams, Ph.D., was
appointed chairman of the
board of directors at Gamida Cell Ltd.
Dr. Adams has more
than 30 years of experience in drug discovery and development with a strong
focus on cancer. He currently serves as
president of research and development
at Infinity Pharmaceuticals, where he is
responsible for the full spectrum of drug
discovery, preclinical and clinical development, and regulatory affairs activities.
Before joining Infinity in 2003, Dr. Ad-
ams was the senior VP of drug discovery
and development at Millennium Phar-
maceuticals, where he headed multiple
global drug discovery and development
programs, including the successful Vel-
cade (bortezomib) program. Dr. Adams
also held senior positions in research
and development at LeukoSite (acquired
by Millennium) and at ProScript, as well
as in medicinal chemistry at Boehringer
Ingelheim, where he is credited with dis-
covering Viramune (nevirapine) for HIV.
Dr. Adams has won many awards,
holds more than 40 patents, and has authored more than 100 papers and book
chapters in peer-reviewed journals. He
earned a B.S. from McGill University and
a Ph.D. from the Massachusetts Institute
of Technology. He also received a Doctor
of Science, honoris causa, from McGill
University in 2012.
Gamida Cell develops cellular and
immune therapies for the treatment of
cancer and orphan genetic diseases. The
company’s pipeline of products is being
developed to treat a wide range of condi-
tions including cancer, genetic hemato-
logical diseases such as sickle cell disease
and thalassemia, bone marrow failure
syndromes such as aplastic anemia, ge-
netic metabolic diseases and refractory
autoimmune diseases. The lead product
in development is NiCord, a novel graft
modality for bone marrow transplanta-
tion in patients with high risk hemato-
logical malignancies (blood cancers) such
as leukemia and lymphoma. The interna-
tional, multi-center Phase III registration
study of NiCord is planned to begin be-
fore the end of the year.
“I am delighted to accept the appoint-
ment of chairman,” Dr. Adams says.
“Gamida Cell is on a clear path to bring-
ing NiCord to market and filling an im-
portant unmet need in bone marrow
transplantation. It is my honor to guide
the success of the NiCord program as well
as the other significant clinical and corpo-
rate initiatives of the company.” medadnews
New chairman of the board for Gamida Cell
Kenneth I. Moch has been appointed
president and CEO of Cognition Therapeutics
Inc. Prior to joining Cognition, Moch was a
managing partner of The Salutramed Group,
a strategy consulting ;rm. He brings to Cog-
nition more than 25 years of experience in
creating, managing and ;nancing biomedical
companies, having previously served as pres-
ident and CEO of Chimerix Inc., Alteon Inc.,
Biomedical Enterprises, and Biocyte Corpora-
tion. Moch was also co-founder and VP of The
Liposome Company Inc. Cognition Thera-
peutics is a privately held biopharmaceutical
company whose disease-relevant screening
and novel chemistry platforms have pro-
duced a pipeline of disease-modifying small
molecule drug candidates which are being
developed to treat Alzheimer’s disease and
potentially other neurocognitive disorders.
Jesse Ledger was made president of Nuvo
Pharmaceuticals Inc. Ledger was previously
Nuvo’s VP of business development. John
London, who was Nuvo’s president and CEO,
will continue to lead the company as its CEO.
Nuvo is a commercial healthcare company
with a portfolio of commercial products and
pharmaceutical manufacturing capabilities.
Fred R. Seddiqui is now CEO of Helix Twelve
Pharmaceuticals Inc. Seddiqui brings more
than 30 years of industry experience to Helix
Twelve. He has held various global executive
positions in medical device and biotechnol-
ogy companies. Over the past three years,
Seddiqui has served as an executive advisor
to Helix Twelve and is a member of the board
of directors. Helix Twelve Pharmaceuticals
is focused on the development of precision
therapeutics in areas including women’s
health, heart disease, and cancer.
Dan Chicoine has been appointed CEO on
an interim basis for Crescita Therapeutics Inc.
He replaces Greg Orleski. Chicoine will also
continue to serve as the company’s executive
chairman. Crescita is a commercial dermatology company with a portfolio of over-the-counter and prescription products for the
treatment and care of skin diseases and their
Chris LeMasters was appointed to the newly
created position of executive VP and chief
business o;cer of Mirati Therapeutics Inc.
Before joining Mirati, LeMasters served as
the CEO of Promosome. Mirati is developing
a pipeline of targeted oncology products
intended to treat speci;c genetic and epigenetic drivers of cancer in selected subsets of
cancer patients with unmet needs.
Mark A. McPartland was made VP, Corporate Development and Investor Relations, at
VistaGen Therapeutics Inc. Prior to joining
VistaGen, McPartland served as the VP of
Corporate Development and Communications at Stellar Biotechnologies Inc. VistaGen is
a clinical-stage biopharmaceutical company
dedicated to developing and commercializing innovative product candidates for
patients with CNS diseases and disorders.
Keith Kennedy is now chief ;nancial o;cer
of Veracyte Inc. Kennedy previously was
president and CEO of MCG Capital Corp. He
succeeded Shelly Guyer, who earlier this year
announced her plan to step down as CFO and
has continued in the role to ensure a smooth
transition. Veracyte is a genomic diagnostics
Je; Elliott has
of Exact Sciences
Corp. Elliott, a
research analyst at
Robert W. Baird &
Co., joined Exact
Sciences as VP,
business development and strategy,
in June 2016.
Exact Sciences is
the manufacturer of
Cologuard, the ;rst noninvasive screening test
for colorectal cancer.
David L. Lowrance, CPA, was appointed chief
;nancial o;cer at Savara Pharmaceuticals.
Prior to joining Savara, Lowrance served
as the chief ;nancial o;cer for Edgemont
Pharmaceuticals. Savara Pharmaceuticals is an
emerging specialty pharmaceutical company
focused on rare respiratory diseases.
Christophe Bonny, Ph.D. is now chief scienti;c o;cer of Enterome Biosciences SA. Dr.
Bonny was previously chief scienti;c o;cer
at Bicycle Therapeutics and before that he
worked at Switzerland-based Xigen where he
served as chief scienti;c o;cer and president.
Enterome is a pioneer in the development of
pharmaceuticals and diagnostics based on
the gut microbiome.
Patrick Shea has become chief commercial
o;cer of Egalet Corp. Before joining Egalet,
Shea served as chief commercial o;cer
at Clarus Therapeutics Inc. Egalet is a fully
integrated specialty pharmaceutical company
focused on developing, manufacturing and
commercializing innovative treatments for
pain and other conditions.
Alexandra D.J. Mancini, M.Sc., was made
senior VP, Clinical and Regulatory A;airs, at
InMed Pharmaceuticals Inc. In addition to her
activities via her private consulting company
True North Synergy, Mancini has been an
executive with several biotech companies,
overseeing a wide range of drug development
activities. InMed is a preclinical stage company
that specializes in developing novel therapies
through the research and development into
the extensive pharmacology of cannabinoids
coupled with innovative drug delivery systems.
Gregory L. Larkin, M.D., MS, MSPH, FACEP,
FACEM has joined Nevakar LLC in the newly
created position of VP, Clinical Development.
In addition to his role at Nevakar, Dr. Larkin is
currently adjunct professor of psychiatry at
New York University School of Medicine. Nevakar is a specialty pharmaceutical company
focused on therapies within the injectable and
Helen Stefanovic is director of regulatory
a;airs at Nexus BioPharma Inc. Stefanovic
served as manager, Science Policy, Corporate
Strategic Planning and Policy at P;zer Inc.
Nexus BioPharma is developing a new weight
David Moskowitz is appointed to the newly
created position of VP, Strategy and Corporate
Communications, at Biocept Inc. Moskowitz
was VP, Investor Relations, at Trovagene.
Biocept is a molecular diagnostics company
commercializing and developing proprietary
liquid biopsy tests that provide clinically actionable information to physicians to improve
Debra K. Bowes has joined MaxCyte Inc.
as executive VP, Business and Strategic
Development. Bowes was interim president and CEO of CapGenesis Pharma.
MaxCyte is focused on the discovery,
development, and manufacture of
innovative drugs, including cell therapies
using best-in-class cell modi;cation
Ruby Hofmann has been appointed to
the position of VP, Human Resources and
Organizational Development at Paragon
Bioservices Inc. Hofmann brings more
than 20 years of experience in progressively responsible positions in the human
resource ;eld. Paragon is a contract development and manufacturing organization whose focus is the development and
manufacturing of biopharmaceuticals.
The Pulse of the Pharmaceutical Industry